Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. STRA
STRA logo

STRA Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Strategic Education Inc (STRA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Buy
Latest Price
79.540
1 Day change
-3.21%
52 Week Range
93.450
Analysis Updated At
2026/03/06
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Strategic Education Inc (STRA) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance in Q4 2025, positive revenue growth, significant operating income increase, and a stable dividend policy make it a solid choice. While the stock is currently down 3.35%, this could present a buying opportunity for long-term investors. The technical indicators are neutral, but the stock is trading near a key support level, which could limit further downside risk.

Technical Analysis

The MACD is positive at 0.823, indicating bullish momentum, though it is contracting. RSI is neutral at 50.589, suggesting no overbought or oversold conditions. Moving averages are converging, indicating a lack of a clear trend. Key support is at 80.203, with resistance at 85.085. The stock is trading near its support level, which may act as a floor for further declines.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

The low put-call ratios indicate a bullish sentiment in the options market. Implied volatility is at 29.54, with an IV percentile of 56.97, suggesting moderate volatility expectations.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
9
Buy
6

Positive Catalysts

  • Strong Q4 2025 financial performance with a 49.63% increase in net income and a 58.10% rise in EPS.

  • Dividend declaration of $0.60 per share, reflecting financial stability and shareholder returns.

  • Analysts maintain a Buy rating with a price target of $95, indicating potential upside from the current price.

Neutral/Negative Catalysts

  • The stock is down 3.35% in regular trading, which could indicate short-term weakness.

  • US enrollment declined more steeply than forecast in Q4, which may weigh on future growth.

  • Neutral sentiment from hedge funds and insiders, with no significant trading trends.

Financial Performance

In Q4 2025, revenue increased by 3.77% YoY to $323.21M. Net income surged by 49.63% YoY to $37.91M, and EPS rose by 58.10% YoY to 1.66. Operating income grew by 35%, with an operating margin of 16.9%. Gross margin improved to 50.51%, up 8.81% YoY, reflecting strong operational efficiency.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts maintain a positive outlook on STRA. Truist lowered the price target to $95 from $105 but reiterated a Buy rating, citing EBITDA strength driven by cost-cutting and AI-driven efficiencies. The stock has room for upside based on the revised price target.

Wall Street analysts forecast STRA stock price to rise
3 Analyst Rating
Wall Street analysts forecast STRA stock price to rise
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 82.180
sliders
Low
85
Averages
95
High
105
Current: 82.180
sliders
Low
85
Averages
95
High
105
Truist
Jasper Bibb
Buy
downgrade
$105 -> $95
AI Analysis
2026-03-02
Reason
Truist
Jasper Bibb
Price Target
$105 -> $95
AI Analysis
2026-03-02
downgrade
Buy
Reason
Truist analyst Jasper Bibb lowered the firm's price target on Strategic Education to $95 from $105 and keeps a Buy rating on the shares. The company reported a mixed Q4 where US enrollment declined more steeply than forecast, but EBITDA beat on a combination of cost cutting and AI-driven efficiencies, the analyst tells investors in a research note.
Morgan Stanley
Terence Flynn
Overweight
maintain
$120 -> $125
2025-12-12
Reason
Morgan Stanley
Terence Flynn
Price Target
$120 -> $125
2025-12-12
maintain
Overweight
Reason
Morgan Stanley analyst Terence Flynn raised the firm's price target on Structure Therapeutics to $125 from $120 and keeps an Overweight rating on the shares. The firm expects many of the policy overhangs that dominated the biopharma conversation this year to wane in 2026, bringing the focus back to fundamentals, the analyst tells investors in a 2026 outlook note for the group.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for STRA
Unlock Now

People Also Watch